1. Beiraghdar F, Panahi Y, Einollahi B, Torkaman M, Mohammadi R, Marzony ET, Sahebkar A (2012a) Investigation of the efficacy of a biogeneric recombinant human erythropoietin alfa in the correction of post-transplantation anemia: a randomized comparative trial with Eprex. Clin Lab 58(11-12):1179–1185
2. Beiraghdar F, Panahi Y, Einollahi B, Nemati E, Ghadiani MH, Sahebkar A, Maghsoudi N, Marzony ET (2012b) Investigation of the efficacy of a biogeneric recombinant human erythropoietin alfa in the management of renal anemia in patients on hemodialysis: a multi-center clinical trial. Clin Lab 58(7-8):737–745
3. Bennett CL, Spiegel DM, Macdougall IC, Norris L, Qureshi ZP, Sartor O, Lai SY, Tallman MS, Raisch DW, Smith SW, Silver S, Murday AS, Armitage JO, Goldsmith D (2012) A review of safety, efficacy, and utilization of erythropoietin, darbepoetin, and peginesatide for patients with cancer or chronic kidney disease: a report from the Southern Network on Adverse Reactions (SONAR). Semin Thromb Hemost 38(8):783–796
4. Bezwoda WR, Seymour L, Dansey RD (1995) High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: a randomized trial. J Clin Oncol 13(10):2483–2489
5. Bohlius J, Weingart O, Trelle S, Engert A (2006) Cancer-related anemia and recombinant human erythropoietin--an updated overview. Nat Clin Pract Oncol 3(3):152–164